<DOC>
	<DOCNO>NCT01325818</DOCNO>
	<brief_summary>The purpose study compare effect pravastatin rosuvastatin coronary plaque characteristic patient stable angina pectoris .</brief_summary>
	<brief_title>The Effects Pravastatin Rosuvastatin Coronary Plaques Patients With Stable Angina Pectoris</brief_title>
	<detailed_description>Previous mega trial demonstrate lipid-lowering therapy HMG-CoA reductase inhibitor individual high risk cardiovascular disease reduces incidence coronary heart disease . NCEP ATP-III suggest advantage intensive lipid lower therapy goal reduce LDL-C 70 mg/dL patient categorize high risk . In Japan , Japan Atherosclerosis Society ( JAS ) Guidelines Diagnosis Treatment Atherosclerotic Cardiovascular Diseases 2002 recommend LDL-C goal patient coronary heart disease ( CHD ) 100 mg/dL . However , satisfactory evidence whether investigator need low LDL-C level le 70mg/dL Japanese population . Recently , research diagnosis coronary plaque show significant advance . The REVERSAL study patient history CHD , diagnosis intravascular ultrasound ( IVUS ) , suggest intensive lipid lower therapy atorvastatin ( 80 mg/day ) associate growth plaque ( -0.4 % compare baseline ) , whereas therapy pravastatin ( 40 mg/day ) show slight increase ( 2.7 % ) plaque volume 18 month Western population . MEGA study show lipid lower therapy pravastatin ( 10-20 mg/day ) associate 33 % reduction coronary heart disease incidence primary prevention Japanese patient . However , effect lipid lower therapy secondary prevention cardiovascular event unknown . Relative plaque regression rate intensive moderate lipid lowering therapy would clarify ideal level target LDL-C Japanese population . Furthermore , different effect coronary plaque pravastatin rosuvastatin different LDL-C lower effect different affinity arterial tissue would determine superior lipid lower regimen affect coronary plaque volume . Therefore , aim present study evaluate whether would lipid lower therapy difference term composition coronary artery plaque patient stable angina pectoris ( SAP ) use integrate backscatter intravascular ultrasound ( IB-IVUS ) optical coherence tomography ( OCT ) .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>1 . Patients diagnose stable angina pectoris , successful percutaneous coronary intervention ( PCI ) perform intravascular ultrasound ( IVUS ) optical coherence tomography ( OCT ) guidance . 2 . Patients coronary plaque ( ≧ 500 µm thickness % plaque 20 % ≧ 5 mm distal proximal previously treat area branch coronary artery . 3 . Patients dyslipidemia define follow criterion : TC ≧ 220 mg/dL LDLC ≧ 140 mg/dL Cholesterollowering treatment allow accord investigator 's judgment LDLC ≧ 100 mg/dL TC ≧ 180mg/dL . Patients cholesterollowering treatment LDLC ≦ 120 mg/dL 4 . Patients 20 year old time consent . 5 . Patients write consent volition provide sufficient explanation participation clinical trial . 1 . Patients bypass graft instent restenosis site PCI . 2 . Patients receive PCI past lesion evaluation coronary plaque volume plan . 3 . Patients plaques nonculprit site might receive PCI treatment period . 4 . Patients receive lipidlowering drug ( fibrates , probucol , nicotinic acid , cholestyramine cholesterol absorption inhibitor ) . 5 . Patients familial hypercholesterolemia . 6 . Patients cardiogenic shock . 7 . Patients receive cyclosporine . 8 . Patients allergy pravastatin rosuvastatin . 9 . Patients hepatobiliary disorder . 10 . Pregnant woman , woman suspect pregnant , lactating woman . 11 . Patients renal disorder ( Cr≧2.0mg/dL ) undergo dialysis . 12 . Patients ineligible opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Coronary Disease</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Stable Angina Pectoris</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Arteriosclerosis</keyword>
	<keyword>Arterial Occlusive Diseases</keyword>
	<keyword>Vascular Diseases Pravastatin</keyword>
	<keyword>Rosuvastatin</keyword>
	<keyword>Anticholesteremic Agents</keyword>
	<keyword>Antilipemic Agents</keyword>
	<keyword>Antimetabolites</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
</DOC>